Randomized, Placebo Controlled Study of the Effect of Propentofylline on Survival Time and Quality of Life of Cats with Feline Infectious Peritonitis

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2011 Nov 19

PMID 22092616

Citations 28

Authors

Y Fischer

S Ritz

K Weber

C Sauter-Louis

K Hartmann

Affiliations

Soon will be listed here.

Abstract

Background: Currently there is no drug proven to effectively treat cats with feline infectious peritonitis (FIP).

Hypothesis: Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.

Animals: Twenty-three privately owned cats with FIP.

Methods: Placebo-controlled double-blind trial. FIP was confirmed by histology or immunostaining of feline coronavirus (FCoV) antigen in effusion or tissue macrophages or both. The cats were randomly selected for treatment with either PPF or placebo. All cats received additional treatment with glucocorticoids, antibiotics, and low molecular weight heparin according to methods.

Results: There was no statistically significant difference in the survival time of cats treated with PPF (8 days, 95% CI 5.4-10.6) versus placebo (7.5 days, 95% CI 4.4-9.6). The median survival time of all cats was 8 days (4-36 days). There was neither a difference in quality of life (day 7, P = .892), in the amount of effusion (day 7, P = .710), the tumor necrosis factor-alpha (TNF-α) concentration (day 7, P = .355), nor in any other variable investigated in this study, including a complete blood count, and a small animal biochemistry profile.

Conclusions And Clinical Importance: This study did not detect an effect of PPF on the survival time, the quality of life, or any clinical or laboratory parameter in cats with FIP. Therefore, PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.

Citing Articles

A review of feline infectious peritonitis virus infection.

Solikhah T, Agustin Q, Damaratri R, Siwi D, Rafiuttaqi G, Hartadi V Vet World. 2025; 17(11):2417-2432.

PMID: 39829669 PMC: 11736369. DOI: 10.14202/vetworld.2024.2417-2432.

Alpha-1-Acid Glycoprotein Quantification via Spatial Proximity Analyte Reagent Capture Luminescence Assay: Application as Diagnostic and Prognostic Marker in Serum and Effusions of Cats with Feline Infectious Peritonitis Undergoing GS-441524 Therapy.

Helfer-Hungerbuehler A, Spiri A, Meili T, Riond B, Krentz D, Zwicklbauer K Viruses. 2024; 16(5).

PMID: 38793672 PMC: 11125897. DOI: 10.3390/v16050791.

Feline infectious peritonitis: A comprehensive evaluation of clinical manifestations, laboratory diagnosis, and therapeutic approaches.

Moyadee W, Sunpongsri S, Choowongkomon K, Roytrakul S, Rattanasrisomporn A, Tansakul N J Adv Vet Anim Res. 2024; 11(1):19-26.

PMID: 38680809 PMC: 11055576. DOI: 10.5455/javar.2024.k742.

Treatment of Three Ferrets Diagnosed with Ferret Systemic Coronaviral Disease Using the Nucleoside Analogue GS-441524.

Puffal J, Neece A, Scaletti F Animals (Basel). 2024; 14(6).

PMID: 38540014 PMC: 10967646. DOI: 10.3390/ani14060916.

Etiologies of nontraumatic feline uveitis in the UK: A retrospective observational study of 72 cats.

Salih A, Giannikaki S, Escanilla N, Ioannides-Hoey C, Best M Open Vet J. 2023; 13(9):1195-1204.

PMID: 37842107 PMC: 10576583. DOI: 10.5455/OVJ.2023.v13.i9.15.

References

Hartmann K . Feline infectious peritonitis. Vet Clin North Am Small Anim Pract. 2005; 35(1):39-79, vi. PMC: 7114919. DOI: 10.1016/j.cvsm.2004.10.011. View

Hartmann K, Kuffer M . Karnofsky's score modified for cats. Eur J Med Res. 1998; 3(1-2):95-8. View

Gross W . New developments in the treatment of systemic vasculitis. Curr Opin Rheumatol. 1994; 6(1):11-9. DOI: 10.1097/00002281-199401000-00003. View

Norris J, Bosward K, White J, Baral R, Catt M, Malik R . Clinicopathological findings associated with feline infectious peritonitis in Sydney, Australia: 42 cases (1990-2002). Aust Vet J. 2005; 83(11):666-73. PMC: 7159746. DOI: 10.1111/j.1751-0813.2005.tb13044.x. View

Peterson J, Couto C, Wellman M . Hemostatic disorders in cats: a retrospective study and review of the literature. J Vet Intern Med. 1995; 9(5):298-303. DOI: 10.1111/j.1939-1676.1995.tb01088.x. View

Meiners I, Hauschildt S, Nieber K, Munch G . Pentoxyphylline and propentophylline are inhibitors of TNF-alpha release in monocytes activated by advanced glycation endproducts. J Neural Transm (Vienna). 2004; 111(3):441-7. DOI: 10.1007/s00702-003-0066-y. View

Foley J, Poland A, Carlson J, Pedersen N . Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. J Am Vet Med Assoc. 1997; 210(9):1313-8. View

Torigoe R, Hayashi T, Anegawa S, Harada K, Toda K, Maeda K . Effect of propentofylline and pentoxifylline on cerebral blood flow using 123I-IMP SPECT in patients with cerebral arteriosclerosis. Clin Ther. 1994; 16(1):65-73. View

Gamble J, Harlan J, Klebanoff S, Vadas M . Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985; 82(24):8667-71. PMC: 391497. DOI: 10.1073/pnas.82.24.8667. View

10.

Shaw S, Shah M, Williams S, Fildes J . Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009; 11(2):113-8. PMC: 2639411. DOI: 10.1093/eurjhf/hfn040. View

11.

Stursberg U, Zenker I, Hecht S, Hartmann K, Schulz B . Use of propentofylline in feline bronchial disease: prospective, randomized, positive-controlled study. J Am Anim Hosp Assoc. 2010; 46(5):318-26. DOI: 10.5326/0460318. View

12.

Strieter R, Remick D, Ward P, Spengler R, Lynch 3rd J, Larrick J . Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988; 155(3):1230-6. DOI: 10.1016/s0006-291x(88)81271-3. View

13.

Nathan C . Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 1987; 80(6):1550-60. PMC: 442423. DOI: 10.1172/JCI113241. View

14.

Zabel P, Schade F, Schlaak M . Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology. 1993; 187(3-5):447-63. DOI: 10.1016/S0171-2985(11)80356-6. View

15.

Watari T, Kaneshima T, Tsujimoto H, Ono K, Hasegawa A . Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats. J Vet Med Sci. 1998; 60(5):657-9. DOI: 10.1292/jvms.60.657. View

16.

Ritz S, Egberink H, Hartmann K . Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 2008; 21(6):1193-7. PMC: 7197507. DOI: 10.1892/06-302.1. View

17.

Hartmann K, Binder C, Hirschberger J, Cole D, Reinacher M, Schroo S . Comparison of different tests to diagnose feline infectious peritonitis. J Vet Intern Med. 2003; 17(6):781-90. PMC: 7197515. DOI: 10.1111/j.1939-1676.2003.tb02515.x. View

18.

Ishida T, Shibanai A, Tanaka S, Uchida K, Mochizuki M . Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med Surg. 2004; 6(2):107-9. PMC: 7129501. DOI: 10.1016/j.jfms.2003.08.011. View

19.

Pohlman T, Stanness K, Beatty P, Ochs H, Harlan J . An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986; 136(12):4548-53. View

20.

Tsai H, Chueh L, Lin C, Su B . Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. J Feline Med Surg. 2011; 13(2):74-80. PMC: 7129202. DOI: 10.1016/j.jfms.2010.09.014. View